221 related articles for article (PubMed ID: 7648757)
21. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
[TBL] [Abstract][Full Text] [Related]
22. Changing role of carbapenems in the treatment of lower respiratory tract infections.
Lode H; Hamacher J; Eller J; Schaberg T
Scand J Infect Dis Suppl; 1995; 96():17-23. PubMed ID: 7652498
[TBL] [Abstract][Full Text] [Related]
23. Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I.
Fukasawa M; Sumita Y; Harabe ET; Tanio T; Nouda H; Kohzuki T; Okuda T; Matsumura H; Sunagawa M
Antimicrob Agents Chemother; 1992 Jul; 36(7):1577-9. PubMed ID: 1510457
[TBL] [Abstract][Full Text] [Related]
24. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.
Mohr JF
Clin Infect Dis; 2008 Sep; 47 Suppl 1():S41-51. PubMed ID: 18713049
[TBL] [Abstract][Full Text] [Related]
25. Overview of a new carbapenem, panipenem/betamipron.
Shimada J; Kawahara Y
Drugs Exp Clin Res; 1994; 20(6):241-5. PubMed ID: 7758396
[TBL] [Abstract][Full Text] [Related]
26. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
[TBL] [Abstract][Full Text] [Related]
27. Meropenem: evaluation of a new generation carbapenem.
Blumer JL
Int J Antimicrob Agents; 1997 Mar; 8(2):73-92. PubMed ID: 18611786
[TBL] [Abstract][Full Text] [Related]
28. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients.
Isla A; Maynar J; Sánchez-Izquierdo JA; Gascón AR; Arzuaga A; Corral E; Pedraz JL
J Clin Pharmacol; 2005 Nov; 45(11):1294-304. PubMed ID: 16239363
[TBL] [Abstract][Full Text] [Related]
29. The disposition and metabolism of meropenem in laboratory animals and man.
Harrison MP; Moss SR; Featherstone A; Fowkes AG; Sanders AM; Case DE
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():265-77. PubMed ID: 2808212
[TBL] [Abstract][Full Text] [Related]
30. The effect of borneol on the concentration of meropenem in rat brain and blood.
Xin HL; He XR; Li W; Zhou ZD; Zhang S; Wang GJ
J Asian Nat Prod Res; 2014; 16(6):648-57. PubMed ID: 24827508
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men.
Ljungberg B; Nilsson-Ehle I
Antimicrob Agents Chemother; 1992 Jul; 36(7):1437-40. PubMed ID: 1510440
[TBL] [Abstract][Full Text] [Related]
32. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH
Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
Tegeder I; Neumann F; Bremer F; Brune K; Lötsch J; Geisslinger G
Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
[TBL] [Abstract][Full Text] [Related]
34. Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes.
Yousif T; Pooyeh S; Hannemann J; Baumann J; Tauber R; Baumann K
Int J Clin Pharmacol Ther; 1999 Oct; 37(10):475-86. PubMed ID: 10543314
[TBL] [Abstract][Full Text] [Related]
35. Meropenem pharmacokinetics in children and adolescents receiving hemodialysis.
Goldstein SL; Murry DJ; May S; Aleksic A; Sowinski KM; Blaney S
Pediatr Nephrol; 2001 Dec; 16(12):1015-8. PubMed ID: 11793091
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
37. Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?
Varghese JM; Jarrett P; Wallis SC; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
J Antimicrob Chemother; 2015 Feb; 70(2):528-33. PubMed ID: 25336163
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients.
Du X; Li C; Kuti JL; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2006 Jan; 46(1):69-75. PubMed ID: 16397286
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium].
Fujii R; Meguro H; Arimasu O; Yoshioka H; Fujita K; Maruyama S; Inyaku F; Nagamatsu I; Wagatsuma Y; Takase A
Jpn J Antibiot; 1986 Jul; 39(7):1912-37. PubMed ID: 3464785
[TBL] [Abstract][Full Text] [Related]
40. Plasma pharmacokinetics and urine concentrations of meropenem in ewes.
Abo El Sooud K
J Vet Pharmacol Ther; 2004 Feb; 27(1):27-30. PubMed ID: 14995963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
